Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hansa Biopharma : ­Sale of shares in Hansa Biopharma AB (publ)

08/26/2020 | 03:16pm EST

Press release Stockholm26 August 2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Nexttobe AB ("Nexttobe") has sold 3.6 million shares in Hansa Biopharma AB (publ) ("Hansa Biopharma") through an accelerated bookbuilding to Swedish and international institutional investors at a price of SEK 240 per share (the "Share Sale").

Following the Share Sale, Nexttobe owns 2,155,379 shares in Hansa Biopharma, corresponding to 4.7% of total shares and 4.8% of total votes outstanding. Subject to customary exceptions or obtaining consent from Carnegie, Nexttobe has agreed not to divest its remaining shares in Hansa Biopharma during a period of 90 days from the Share Sale.

Carnegie Investment Bank AB ("Carnegie") acted as Sole Bookrunner in connection with the Share Sale.

IMPORTANT NOTICE

THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL, OR SOLICITATION OF AN OFFER TO BUY, ANY SECURITIES IN THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") AND MAY NOT BE SOLD IN THE UNITED STATES ABSENT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT. THERE WILL NOT BE A PUBLIC OFFERING OF THE SHARES IN THE UNITED STATES.

THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES OR INVESTMENTS FOR SALE OR A SOLICITATION OF AN OFFER TO BUY SECURITIES OR INVESTMENTS IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL. NO ACTION HAS BEEN TAKEN THAT WOULD PERMIT AN OFFERING OF THE SECURITIES OR POSSESSION OR DISTRIBUTION OF THIS ANNOUNCEMENT IN ANY JURISDICTION WHERE ACTION FOR THAT PURPOSE IS REQUIRED. PERSONS INTO WHOSE POSSESSION THIS ANNOUNCEMENT COMES ARE REQUIRED TO INFORM THEMSELVES ABOUT AND TO OBSERVE ANY SUCH RESTRICTIONS. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

IN MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA") (EACH, A "RELEVANT MEMBER STATE"), THIS ANNOUNCEMENT AND ANY OFFER IF MADE SUBSEQUENTLY IS DIRECTED EXCLUSIVELY AT PERSONS WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF THE PROSPECTUS REGULATION ("QUALIFIED INVESTORS"). FOR THESE PURPOSES, THE EXPRESSION "PROSPECTUS REGULATION" MEANS REGULATION (EU) 2017/1129.

IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER") OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED.

IN CONNECTION WITH THE PLACING, THE BOOKRUNNERS AND ANY OF THEIR AFFILIATES ACTING AS AN INVESTOR FOR ITS OWN ACCOUNT MAY TAKE UP AS A PRINCIPAL POSITION ANY SHARES AND IN THAT CAPACITY MAY RETAIN, PURCHASE OR SELL FOR ITS OWN ACCOUNT SUCH SHARES. IN ADDITION, THE BOOKRUNNERS OR THEIR AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS AND SWAPS WITH INVESTORS IN CONNECTION WITH WHICH THE BOOKRUNNERS (OR THEIR AFFILIATES) MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SHARES. THE BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATION TO DO SO.

THE BOOKRUNNERS ARE ACTING ON BEHALF OF THE SELLER AND NO ONE ELSE IN CONNECTION WITH THE PLACING AND WILL NOT BE RESPONSIBLE TO ANY OTHER PERSON FOR PROVIDING THE PROTECTIONS AFFORDED TO CLIENTS OF THE BOOKRUNNERS OR FOR PROVIDING ADVICE IN RELATION TO THE PLACING.

https://news.cision.com/carnegie/r/sale-of-shares-in-hansa-biopharma-ab--publ-,c3181988

https://mb.cision.com/Main/1266/3181988/1297917.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about HANSA BIOPHARMA AB (PUBL)
01/11HANSA BIOPHARMA : Forecasts FY20 Operating Loss to Widen
MT
01/11HANSA BIOPHARMA : provides business update incl. certain key financials ahead of..
AQ
2020HANSA BIOPHARMA :  Biopharma to present at the 39th Annual J.P. Morgan Healthcar..
AQ
2020HANSA BIOPHARMA : Nomination Committee formed
AQ
2020Hansa Biopharma interim report Jan-Sep 2020
AQ
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
PU
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
AQ
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
PU
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
AQ
2020HANSA BIOPHARMA : certified as a Great Place to Work
AQ
More news
Financials
Sales 2020 35,8 M 4,31 M 4,31 M
Net income 2020 -396 M -47,8 M -47,8 M
Net cash 2020 1 385 M 167 M 167 M
P/E ratio 2020 -19,5x
Yield 2020 -
Capitalization 8 174 M 986 M 986 M
EV / Sales 2020 190x
EV / Sales 2021 74,3x
Nbr of Employees 80
Free-Float 95,9%
Chart HANSA BIOPHARMA AB (PUBL)
Duration : Period :
Hansa Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANSA BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 295,67 SEK
Last Close Price 183,80 SEK
Spread / Highest target 123%
Spread / Average Target 60,9%
Spread / Lowest Target 3,37%
EPS Revisions
Managers and Directors
NameTitle
Søren Tulstrup President & Chief Executive Officer
Ulf Arne Wiinberg Chairman
Christian Kjellman Chief Operating & Scientific Officer
Donato Spota Chief Financial Officer
Achim Kaufhold Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HANSA BIOPHARMA AB (PUBL)-23.54%986
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059